Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 6, 1999, Pages 836-843

  Zhou, Zhengfeng ^a   Vorperian, Vicken R ^a   Gong, Qiuming ^a   Zhang, Shetuan ^a   January, Craig T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Antihistamine; Arrhythmia; I(Kr); Long QT syndrome; Potassium channels

Indexed keywords

ASTEMIZOLE; NORASTEMIZOLE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; TERFENADINE;

ARTICLE; CHANNEL GATING; CONCENTRATION RESPONSE; DRUG ELIMINATION; ELECTROPHYSIOLOGY; HALF LIFE TIME; HEART VENTRICLE ARRHYTHMIA; HUMAN; HUMAN CELL; LONG QT SYNDROME; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL;

EID: 0032995058     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00264.x     Document Type: Article

References (30)

1. 1-receptor antagonists. Allergy 1997;52:67-78.
2. 2. Heykants J, Van Peer A, Woestenborghs R, et al: Dose-proportionality, bioavailability, and steady-slate kinetics of ustemizule in man. Drug Develop Res 1986;8:71-78.
3. 3. Meuldermans W, Hendrickx J, Lauwers W, et al: Excretion and biotransformation of astemizole in rats, guinea-pig, dogs and man. Drug Dev Res 1986;8:37-51.
4. 4. Kamei C, Mio M, Izushi K, et al: Antiallergic effects of major metabolites of astemizole in rats and guinea pigs. Arzneimittelforschung 1991;41:932-936.
5. 5. Handley DA, McCullough JR, Fang KO, et al: Comparative antihistaminic effects of astemizole and a metabolite, norastemizole. (Abstract) Ann Allerg Asthma Immunol 1997;78:144.
6. 6. Rubin PD, DeGraw SS, Krause AC, et al: Pharmacokinetics and pharmacodynamics of norastemizole in normal volunteers. (Abstract) Ann Allerg Asthma Immunol 1997;78:144.
7. 1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ Res 1995; 76:110-119.
8. 8. Suessbrich H, Waldegger S, Lang F, et al: Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996;385:77-80.
9. + channels. Mol Pharmacol 1998; 54:113-121.
10. + channel. Cell 1995;81:299-307.
11. 11. Trudeau MC, Warmke JW, Ganetzki B, et al: HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995;269:92-95.
12. 12. January CT, Zhou Z: Early afterdepolarizations: Mechanisms and possible role in arrhythmias. In Liebman J, ed. Electrocardiology '96: From the Cell to the Body Surface. World Scientific, Inc., Singapore, 1997, pp. 231-240.
13. 13. Sugiyama A, Aye NN, Katahira S, et al: Effects of nonsedating antihistamine, astemizole, on the in situ canine heart assessed by cardiohemodynamic and monophasic action potential monitoring. Toxicol Appl Pharmacol 1997;143:89-95.
14. 14. Vorperian VR, Zhou Z, Mohammad S, et al: Torsades de pointes with an antihistamine metabolite: Potassium channel block with desmethylastemizole. J Am Coll Cardiol 1996;28:1556-1561.
15. 15. Hey JA, del Prado M, Sherwood J, et al : Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittelforschung 1996;46:153-158.
16. 16. Zhang M-Q: Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem 1997;4:171-184.
17. 17. Rubin P, Donoghue A, DeGraw S, et al: Effects of varying doses of norastemizole on histamine induced wheal (W) and Flare (F) responses and ECG. (Abstract) J Allergy Clin Immunol 1998;101:5248.
18. 18. Casale TB, Kessler RJ, Clancy J, et al; Norastemizole does not affect ECG parameters. (Abstract) J Allergy Clin Immunol 1998;101:S245.
19. 19. Zhou Z, Gong Q, Vorperian VR, et al: High affinity block of HERG channels by an astemizole metabolite, desmethylastemizole. (Abstract) Biophys J 1997;72:A225.
20. 20. Zhou Z, Gong Q, Ye B, et al: Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998;74;230-241.
21. 21. Hamill OP, Marty A, Neher E, et al: Improved patch-clamp techniques for high resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981;391:85-100.
22. + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 1997;42: H2534-H2538.
23. + channel family by ebastine. J Pharmacol Exp Ther 1997;281:233-244.
24. 24. Snyders DJ, Chaudhary A: High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 1996;49:949-955.
25. 25. Morgan TK, Sullivan ME: An overview of class III electrophysiological agents: A new generation of antiarrhythmic therapy. Prog Med Chem 1992;29:65-109.
26. + channels. J Cardiovasc Pharmacol 1997;30:42-54.
27. 27. Food and Drug Administration Press Office: FDA Approves Allegra-D, Manufacturer to Withdraw Seldane from Marketplace. FDA Talk Paper. Food and Drug Administration, U.S. Dept of Health and Human Services, December 29, 1997.
28. 28. Woosley RL, Chen Y, Freiman JP, et al: Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269: 1532-1536.
29. 29. Roy M, Dumaine R, Brown A: HERG: A primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996;94:817-823.
30. 30. Yang T, Prakash C, Roden DM, et al: Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol 1995;115:267-274